Metronidazole
important information for the patient.
Grinazole is intended for local treatment of root canal infections of the tooth, following pulp necrosis and its complications.
The active substance of the medicine is metronidazole, used in local treatment of infections.
The medicine is intended for professional use by a dentist.
If the patient is allergic to metronidazole or other imidazoles (substances with a structure similar to metronidazole), para-aminobenzoates, or any of the other ingredients of this medicine (listed in section 6).
Before using the product, a medical history should be taken to check for any allergic reactions.
Tell your doctor or dentist about all medicines you are taking, or have recently taken, and any medicines you plan to take.
There are no reports of interactions with Grinazole used locally in the treatment of root canal infections of the tooth.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Pregnancy:
Caution should be exercised when administering the medicine to pregnant women.
Breastfeeding:
Metronidazole may cause a bitter taste in breast milk, which can cause vomiting in infants, combined with a reluctance to eat.
It is recommended to avoid using metronidazole during breastfeeding.
However, if metronidazole is necessary in the form of Grinazole in a breastfeeding woman, breastfeeding can be considered acceptable provided that the newborn is clinically monitored during the mother's treatment and for 2-3 days after its completion.
Grinazole does not affect the ability to drive vehicles or operate machinery.
Grinazole is used by the dentist during the treatment of root canal infections of the tooth.
The medicine is intended for use only in dental practice.
After cleaning the canal, if there are clinical symptoms of infection, Grinazole paste should be placed in the canal using mechanically driven instruments and closed with temporary cement.
Treatment should be completed 2-3 days later by removing the Grinazole paste from the canal and filling the canal in a standard manner.
There are no reports of overdose.
Like all medicines, Grinazole can cause side effects, although not everybody gets them.
During the visit to the dentist's office, the dentist will carefully monitor the effects of Grinazole.
The frequency of possible side effects listed below is defined as:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1000 people
Very rare: may affect up to 1 in 10,000 people
Not known: frequency cannot be estimated from the available data
Immune system disorders
Not known: hypersensitivity reactions
General disorders and administration site conditions
Not known: periapical irritation, causing exacerbation of symptoms of apical periodontitis.
If you experience any side effects, including any not listed in this leaflet, tell your doctor or dentist.
Side effects can be reported directly to the Department of Post-Marketing Surveillance of Medicinal Products, Medical Devices, and Biocidal Products,
Tel.: + 48 22 49 21 301
Fax: + 48 22 40 21 309
e-mail: ndl@urpl.gov.pl
Reporting side effects will help to gather more information on the safety of the medicine.
Store in a temperature below 25°C.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton after: EXP. The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Grinazole is a white to ivory-colored paste.
A multi-layer tube with HDPE (high-density polyethylene), closed with a white polypropylene cap, containing 4.5 g of paste.
The carton contains one tube.
SEPTODONT
58, rue du Pont de Créteil
94100 Saint-Maur-des-Fossés
France
To obtain information about the medicine, contact the representative of the marketing authorization holder in Poland:
Septodont Polska sp. z o.o.
ul. Taneczna 18 A
02-829 Warsaw
Tel.: 22/ 545 89 50
Fax: 22/ 641 80 21
e-mail: sekretariat@septodont.com.pl
Date of last revision of the leaflet:
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.